In this study, we developed an anti-EGFR antibody-conjugated MB (EGFR-MB) as a targeting agent and investigated the efficacy of BLM delivery using sonoporation with EGFR-MBs in vitro and in vivo in a squamous cell carcinoma model. This evidence concerns the gene EGFR and squamous cell carcinoma.